Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AEON
Upturn stock ratingUpturn stock rating

AEON Biopharma, Inc. (AEON)

Upturn stock ratingUpturn stock rating
$0.76
Last Close (24-hour delay)
Profit since last BUY-14.61%
upturn advisory
WEAK BUY
BUY since 12 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: AEON (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $7.2

1 Year Target Price $7.2

Analysts Price Target For last 52 week
$7.2Target price
Low$0.38
Current$0.76
high$239.76

Analysis of Past Performance

Type Stock
Historic Profit -61.12%
Avg. Invested days 27
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.59M USD
Price to earnings Ratio -
1Y Target Price 7.2
Price to earnings Ratio -
1Y Target Price 7.2
Volume (30-day avg) 1
Beta 0.57
52 Weeks Range 0.38 - 239.76
Updated Date 07/1/2025
52 Weeks Range 0.38 - 239.76
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) 303.48

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -158.88%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE 1.16
Enterprise Value 12746078
Price to Sales(TTM) 97.16
Enterprise Value 12746078
Price to Sales(TTM) 97.16
Enterprise Value to Revenue 201.68
Enterprise Value to EBITDA -5.89
Shares Outstanding 11305400
Shares Floating 7857908
Shares Outstanding 11305400
Shares Floating 7857908
Percent Insiders 24.46
Percent Institutions 14.66

Analyst Ratings

Rating 1
Target Price 7.2
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

AEON Biopharma, Inc.

stock logo

Company Overview

overview logo History and Background

AEON Biopharma, Inc. is a biopharmaceutical company focused on developing botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for a variety of indications, including chronic migraine, cervical dystonia, and gastroparesis. It was founded with the goal of improving treatment options for these debilitating conditions. Specific founding year and early milestones are not clearly stated in readily available resources. Their focus is on regulatory approval and commercialization.

business area logo Core Business Areas

  • Therapeutic Development: Development of ABP-450 for neurological and gastrointestinal disorders.
  • Clinical Trials: Conducting clinical trials to assess the safety and efficacy of ABP-450.
  • Regulatory Affairs: Navigating regulatory approval processes with the FDA.
  • Commercialization: Preparing for the commercial launch of ABP-450 upon approval.

leadership logo Leadership and Structure

AEON Biopharma, Inc. has a leadership team comprised of individuals with experience in the pharmaceutical industry, clinical development, and commercialization. The organizational structure is typical for a biotech company, with departments focused on research and development, clinical operations, regulatory affairs, and commercial strategy.

Top Products and Market Share

overview logo Key Offerings

  • ABP-450 (prabotulinumtoxinA): ABP-450 is AEON's lead product candidate. It is being developed as a botulinum toxin injection for the treatment of chronic migraine, cervical dystonia, and gastroparesis. Market share is currently 0% as the product is not yet approved. Competitors include Allergan (Botox), Ipsen (Dysport), Merz (Xeomin), and Revance Therapeutics (Daxxify). Potential revenue upon approval across indications could be significant, but no concrete data is available currently. Targetting markets currently serviced by Allergan etc

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. The market for botulinum toxin products is well-established, but AEON is attempting to carve a niche through potentially improved efficacy or safety.

Positioning

AEON is positioned as a company seeking to provide alternative treatment options using a botulinum toxin product. The competitive advantage depends on the clinical trial results and the demonstrated efficacy and safety profile of ABP-450 compared to existing products.

Total Addressable Market (TAM)

The total addressable market for botulinum toxin products is estimated to be in the billions of dollars annually across the various indications AEON is targeting. AEON's position depends on successful clinical trials and regulatory approvals and ability to capture some of this current TAM which is dominated by Allergan and others

Upturn SWOT Analysis

Strengths

  • Focused pipeline on botulinum toxin therapeutics
  • Potential for improved efficacy/safety profile compared to existing products
  • Experienced management team in pharmaceutical development

Weaknesses

  • Currently no approved products, leading to zero revenue
  • High dependence on the success of ABP-450
  • Limited financial resources compared to larger pharmaceutical companies

Opportunities

  • Potential to gain market share in the botulinum toxin market upon approval
  • Expansion into new therapeutic indications for ABP-450
  • Partnerships or collaborations with larger pharmaceutical companies

Threats

  • Failure to obtain regulatory approval for ABP-450
  • Competition from established botulinum toxin products
  • Adverse events or safety concerns associated with ABP-450

Competitors and Market Share

competitor logo Key Competitors

  • AGN
  • IPN
  • MRZ
  • RVNC

Competitive Landscape

AEON faces a highly competitive landscape dominated by established players with approved botulinum toxin products. AEON's success depends on demonstrating a superior profile for ABP-450.

Growth Trajectory and Initiatives

Historical Growth: No historical revenue growth due to the company being pre-revenue.

Future Projections: Future growth is dependent on the approval and commercial success of ABP-450. Analyst estimates are not readily available. Would need to pull recent analyst reports for projections.

Recent Initiatives: Recent initiatives include ongoing clinical trials for ABP-450 across the target indications and preparation for regulatory submissions.

Summary

AEON Biopharma is a high-risk, high-reward biopharmaceutical company focused on developing a botulinum toxin product. The company's success hinges on positive clinical trial outcomes and regulatory approval. While the company operates in a competitive market dominated by established players, it has the opportunity to capture market share if its product demonstrates superior efficacy and safety. Investors should carefully consider the risks associated with pre-revenue biotech companies and the potential for clinical trial setbacks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Market share values are estimates. Consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About AEON Biopharma, Inc.

Exchange NYSE MKT
Headquaters Irvine, CA, United States
IPO Launch date 2021-04-12
President, CEO & Director Mr. Robert Bancroft
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.